This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second Opinion: Digging into the Phase 3 POETYK PsA-2 Trial data for Sotyktu in patients with psoriatic arthritis.

Ticker(s): BMY

Who's the expert?

Institution: Texas Orthopedics

Rheumatologist at a very busy multi-specialty, predominantly orthopedics

Manages private practice infusion center

Sees roughly 200 patients with gout

Interview Goal
to discuss the current standard of care and the potential of Sotyktu (deucravaccitinib) for the treatment of psoriatic arthritis.

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.